Cargando…
Atezolizumab plus bevacizumab versus sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: a cost‐effectiveness analysis
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7743015/ https://www.ncbi.nlm.nih.gov/pubmed/33159490 http://dx.doi.org/10.1002/cac2.12110 |
| _version_ | 1783624121571082240 |
|---|---|
| author | Hou, Yanli Wu, Bin |
| author_facet | Hou, Yanli Wu, Bin |
| author_sort | Hou, Yanli |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7743015 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-77430152020-12-18 Atezolizumab plus bevacizumab versus sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: a cost‐effectiveness analysis Hou, Yanli Wu, Bin Cancer Commun (Lond) Letters to the Editor John Wiley and Sons Inc. 2020-11-07 /pmc/articles/PMC7743015/ /pubmed/33159490 http://dx.doi.org/10.1002/cac2.12110 Text en © 2020 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Letters to the Editor Hou, Yanli Wu, Bin Atezolizumab plus bevacizumab versus sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: a cost‐effectiveness analysis |
| title | Atezolizumab plus bevacizumab versus sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: a cost‐effectiveness analysis |
| title_full | Atezolizumab plus bevacizumab versus sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: a cost‐effectiveness analysis |
| title_fullStr | Atezolizumab plus bevacizumab versus sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: a cost‐effectiveness analysis |
| title_full_unstemmed | Atezolizumab plus bevacizumab versus sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: a cost‐effectiveness analysis |
| title_short | Atezolizumab plus bevacizumab versus sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: a cost‐effectiveness analysis |
| title_sort | atezolizumab plus bevacizumab versus sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: a cost‐effectiveness analysis |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7743015/ https://www.ncbi.nlm.nih.gov/pubmed/33159490 http://dx.doi.org/10.1002/cac2.12110 |
| work_keys_str_mv | AT houyanli atezolizumabplusbevacizumabversussorafenibasfirstlinetreatmentforunresectablehepatocellularcarcinomaacosteffectivenessanalysis AT wubin atezolizumabplusbevacizumabversussorafenibasfirstlinetreatmentforunresectablehepatocellularcarcinomaacosteffectivenessanalysis |